Thymulin

FTS, Facteur thymique serique

Grade C: Preliminary or limited human evidence

TL;DR: Thymulin (facteur thymique serique, FTS) is a nonapeptide naturally secreted by thymic epithelial cells in a zinc-dependent active form. Its biology is better characterized than most peptide bioregulators: it is an endogenous human hormone with a known receptor, a defined zinc-binding requirement for bioactivity, and a measurable serum concentration that declines with age. The human evidence includes observational studies documenting low thymulin levels in malnutrition, zinc deficiency, anorexia nervosa, and aging, as well as studies in myasthenia gravis patients. An open (unblinded) trial of FTS-Zn in rheumatoid arthritis patients was published in the 1980s and reported immunological changes, but this was uncontrolled. A critical distinction: double-blind, placebo-controlled trials in rheumatoid arthritis were conducted using nonathymulin, a synthetic structural analog -- not thymulin itself. The results from those trials do not automatically transfer to thymulin. Most of the in vivo intervention data comes from animal models (NZB mice, rodent immunodeficiency models) and in vitro work on human thymic epithelial cells. No controlled human efficacy trials for thymulin as a therapeutic agent have been published. The connection between zinc supplementation, thymulin secretion, and immune function in zinc-deficient populations is the most grounded part of the evidence base, but this implicates zinc repletion as the intervention, not exogenous thymulin.

Key Takeaways

Grade C: Preliminary or limited human evidence
Not FDA approved: Thymulin is not FDA-approved for any therapeutic indication. It is an endogenous peptide that has been studied as a pharmaceutical candidate but has not completed the approval process in any major Western regulatory jurisdiction. The nonathymulin analog trials (which showed modest, inconsistent results in RA) are the closest it has come to controlled human evaluation under any regulatory framework.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

Thymulin is secreted by thymic epithelial cells as a zinc-bound nonapeptide. In its active zinc-bound form (Zn-FTS), it binds thymulin receptors on T-lymphocyte precursors and promotes their differentiation and acquisition of T-cell surface markers. It also appears to modulate cytokine signaling, including IL-1-driven regulation of its own secretion. Serum levels are suppressed by zinc deficiency, malnutrition, and aging, which has led to interest in it as a marker and potential mediator of age-related immune decline (thymic involution).

Evidence

Thymulin (facteur thymique serique, FTS) is a nonapeptide naturally secreted by thymic epithelial cells in a zinc-dependent active form. Its biology is better characterized than most peptide bioregulators: it is an endogenous human hormone with a known receptor, a defined zinc-binding requirement for bioactivity, and a measurable serum concentration that declines with age. The human evidence includes observational studies documenting low thymulin levels in malnutrition, zinc deficiency, anorexia nervosa, and aging, as well as studies in myasthenia gravis patients. An open (unblinded) trial of FTS-Zn in rheumatoid arthritis patients was published in the 1980s and reported immunological changes, but this was uncontrolled. A critical distinction: double-blind, placebo-controlled trials in rheumatoid arthritis were conducted using nonathymulin, a synthetic structural analog -- not thymulin itself. The results from those trials do not automatically transfer to thymulin. Most of the in vivo intervention data comes from animal models (NZB mice, rodent immunodeficiency models) and in vitro work on human thymic epithelial cells. No controlled human efficacy trials for thymulin as a therapeutic agent have been published. The connection between zinc supplementation, thymulin secretion, and immune function in zinc-deficient populations is the most grounded part of the evidence base, but this implicates zinc repletion as the intervention, not exogenous thymulin.

Safety and risks

No controlled human safety data for administered thymulin exist. The open RA trial and observational studies do not report systematic adverse events, but were not designed to capture them. Because thymulin is an endogenous immunomodulatory hormone, exogenous administration raises theoretical risks of immune dysregulation, particularly in autoimmune contexts. Zinc toxicity is a distinct but separate concern if thymulin preparations include zinc supplementation. No long-term safety data exist.

Interactions

Zinc status directly modulates thymulin bioactivity; zinc deficiency renders the peptide inactive. Combining exogenous thymulin with immunomodulatory drugs, corticosteroids, or biologics has not been studied and carries unpredictable interaction risk.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Thymulin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).